FierceBiotech: Odyssey starts journey with $218M for 7 assets across cancer, inflammation with IFM, Scorpion founder at the helm

Kyle LaHucik

Nine months young and five months since hiring its first employee, Odyssey Therapeutics has secured $218 million to bankroll seven programs across cancer and inflammation. Its first study in humans will be in late 2023 or early 2024. 

Read more